Latest Trials
Latest News
FAQ
Pharmaceutical Companies
Pharma Details
CHUGAI PHARMACEUTICAL CO., LTD.
🇯🇵
Japan
Country
🇯🇵
Japan
Ownership
Public, Subsidiary
Established
1925-03-10
Employees
7.6K
Market Cap
$83.6B
Website
http://www.chugai-pharm.co.jp
Clinical Trials
Related News
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA012JP
Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: MRA(Tocilizumab)
Subscribe
First Posted Date
2005-09-05
Last Posted Date
2013-08-09
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
241
Registration Number
NCT00144547
Subscribe
Long-term Treatment Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Phase 3
Completed
Conditions
Polyarticular Juvenile Idiopathic Arthritis
Interventions
Drug: MRA(Tocilizumab)
Subscribe
First Posted Date
2005-09-05
Last Posted Date
2009-12-23
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
19
Registration Number
NCT00144625
Subscribe
Long-term Treatment Study of MRA for Rheumatoid Arthritis (RA) From Study MRA213JP
Phase 3
Completed
Conditions
Rheumatoid Arthritis
Interventions
Drug: MRA (Tocilizumab)
Subscribe
First Posted Date
2005-09-05
Last Posted Date
2009-12-23
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
115
Registration Number
NCT00144534
Subscribe
Long-term Treatment Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
Phase 3
Completed
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Drug: MRA(Tocilizumab)
Subscribe
First Posted Date
2005-09-05
Last Posted Date
2009-12-23
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
60
Registration Number
NCT00144612
Subscribe
Clinical Pharmacology Study of MRA in Patient With Rheumatoid Arthritis (RA) With Renal Impairment
Not Applicable
Completed
Conditions
Rheumatoid Arthritis
Subscribe
First Posted Date
2005-09-05
Last Posted Date
2008-12-15
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
14
Registration Number
NCT00144573
Subscribe
Drug-Drug Interaction Study of MRA in Patient With Rheumatoid Arthritis (RA)
Not Applicable
Completed
Conditions
Rheumatoid Arthritis
Subscribe
First Posted Date
2005-09-05
Last Posted Date
2008-12-15
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
31
Registration Number
NCT00144560
Subscribe
Study of MRA for Systemic Juvenile Idiopathic Arthritis (sJIA)
Phase 3
Completed
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Drug: MRA(Tocilizumab)
Drug: placebo
Subscribe
First Posted Date
2005-09-05
Last Posted Date
2008-07-30
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
56
Registration Number
NCT00144599
Subscribe
Study of MRA for Polyarticular Juvenile Idiopathic Arthritis (pJIA)
Phase 3
Completed
Conditions
Systemic Juvenile Idiopathic Arthritis
Interventions
Drug: MRA(Tocilizumab)
Subscribe
First Posted Date
2005-09-05
Last Posted Date
2008-07-30
Lead Sponsor
Chugai Pharmaceutical
Target Recruit Count
19
Registration Number
NCT00144664
Subscribe
Monoclonal Antibody Compared With Zoledronate in Treating Women With Breast Cancer and Bone Metastases
Phase 1
Completed
Conditions
Breast Cancer
Hypercalcemia of Malignancy
Metastatic Cancer
Pain
Subscribe
First Posted Date
2003-05-07
Last Posted Date
2013-05-15
Lead Sponsor
Chugai Pharmaceutical
Registration Number
NCT00060138
Locations
🇺🇸
Ireland Cancer Center, Cleveland, Ohio, United States
Subscribe
Prev
1
2
3
4
5
6
Next
© Copyright 2024. All Rights Reserved by MedPath
Home
Terms & Conditions
Privacy Policy